Noted Urologist Calls Attention to Implications of Flawed Prostate Specific Antigen Data in SEER
Editorial in The Journal of Urology®
Warns of Impact on Previous Research Results
Editorial in The Journal of Urology® Warns of Impact on Previous Research Results
The National Cancer Institute (NCI) recently announced that it had removed all prostate specific antigen (PSA) data from the SEER (Surveillance, Epidemiology and End Results) and SEER-Medicare programs. The PSA data were removed after quality control checks revealed that a substantial number of PSA values included in the programs were incorrect. An editorial published in The Journal of Urology® explores the ramifications of the removal of these data for researchers, clinicians, and administrators within the health care community, as well as the use and accuracy of large administrative datasets in general.
The SEER program, initiated by NCI in 1973 and one of the oldest and most highly regarded cancer registries in the world, is legislatively mandated to collect cancer incidence and survival data from 17 population-based cancer registries across the United States, representing roughly 28% of the U.S. population. The SEER-Medicare dataset links the cancer information in SEER to administrative claims data for patients in SEER covered under the Medicare program.
David F. Penson, MD, MPH, Director of the Center for Surgical Quality and Outcomes Research, Professor and Chair, Department of Urologic Surgery at Vanderbilt University, and the VA Tennessee Valley Geriatric Research, Education, and Clinical Center, Nashville, TN, cautions that withdrawal of these data from SEER will have two major impacts on the field of prostate cancer research.
“First, ongoing analyses using SEER and SEER-Medicare that include PSA data will have to be redesigned in light of the problems with these data. Simply put, journals will not be able to accept SEER studies that rely on the PSA data as a primary variable of interest, including those that use PSA in risk stratification systems to adjust for confounding or in cohort identification. This effect is relatively straightforward and should not cause great problems in the field going forward.”
According to the author, “The greater problem, however, is the impact of the flawed PSA data on the existing urological literature. SEER and SEER-Medicare data have been used to address questions about screening and effectiveness of treatments for localized and advanced disease. How can we now trust these studies given the problems with the PSA data?”
Dr. Penson cautions that while large administrative databases like SEER have tremendous value when answering difficult clinical and health care policy questions if used properly, researchers should reconsider publishing secondary data analyses just because the data are relatively easy to obtain and analyze. “We cannot ask these datasets to answer questions that they are not capable of answering. In that situation we have to do the really hard work and collect primary data. It’s time for us to stop doing big data fishing expeditions and taking the easy way out.”
Notes for editors
“The Power and the Peril of Large Administrative Databases,” by David F. Penson. DOI: http://dx.doi.org/10.1016/j.juro.2015.05.002 . Published online in advance of The Journal of Urology®, Volume 194, Issue 1 (July 2015) by Elsevier.
Full text of this article is available to credentialed journalists upon request; contact Linda Gruner at 212-633-3923 or firstname.lastname@example.org to obtain copies. Journalists wishing to interview David F. Penson may contact him via Craig Boerner, Media Director, National News Director, Vanderbilt University Medical Center, at +1 615-322-4747, +1 615-479-6374 (cell), or email@example.com.
About The Journal of Urology®
Established in 1917, The Journal of Urology® (www.jurology.com) is the official journal of the American Urological Association (www.auanet.org). It is the most widely read and highly cited journal in the field. It brings to its readership all the clinically relevant information needed to stay at the forefront of this dynamic field. This top-ranking journal presents investigative studies on critical areas of research and practice, survey articles providing short condensations of the best and most important urology literature worldwide and practice-oriented reports on interesting clinical observations.
Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a world-leading provider of information and analytics to professionals and business customers, in a wide range of industries. www.elsevier.com